These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15275632)

  • 21. Dominant negative insulin-like growth factor-1 receptor inhibits neointimal formation through suppression of vascular smooth muscle cell migration and proliferation, and induction of apoptosis.
    Lim HJ; Park HY; Ko YG; Lee SH; Cho SY; Lee EJ; Jameson JL; Jang Y
    Biochem Biophys Res Commun; 2004 Dec; 325(3):1106-14. PubMed ID: 15541402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing restenosis after angioplasty: a multistage approach.
    Zargham R
    Clin Sci (Lond); 2008 Feb; 114(4):257-64. PubMed ID: 18194134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation in accelerated atherosclerosis.
    Vogt F; Zernecke A; Beckner M; Krott N; Bosserhoff AK; Hoffmann R; Zandvoort MA; Jahnke T; Kelm M; Weber C; Blindt R
    J Am Coll Cardiol; 2008 Jul; 52(4):302-11. PubMed ID: 18634987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of vascular stem cells in atherogenesis and post-angioplasty restenosis.
    Qian H; Yang Y; Li J; Huang J; Dou K; Yang G
    Ageing Res Rev; 2007 Aug; 6(2):109-27. PubMed ID: 17324640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level.
    Yamawaki T; Yamada A; Fukumoto Y; Kishi T; Sobashima A; Kuwata K; Nakamura R; Sekiya M; Ando H; Okamatsu S
    Fukuoka Igaku Zasshi; 2007 Jun; 98(6):260-9. PubMed ID: 17665547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins effect on smooth muscle cell proliferation.
    Bellosta S; Arnaboldi L; Gerosa L; Canavesi M; Parente R; Baetta R; Paoletti R; Corsini A
    Semin Vasc Med; 2004 Nov; 4(4):347-56. PubMed ID: 15861311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The year in atherothrombosis.
    Moreno PR; Fuster V
    J Am Coll Cardiol; 2004 Dec; 44(11):2099-110. PubMed ID: 15582305
    [No Abstract]   [Full Text] [Related]  

  • 31. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
    Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
    J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling.
    Sedding DG; Tröbs M; Reich F; Walker G; Fink L; Haberbosch W; Rau W; Tillmanns H; Preissner KT; Bohle RM; Langheinrich AC
    Circ Res; 2009 May; 104(10):1192-200. PubMed ID: 19372464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells.
    Ogawa D; Nomiyama T; Nakamachi T; Heywood EB; Stone JF; Berger JP; Law RE; Bruemmer D
    Circ Res; 2006 Apr; 98(7):e50-9. PubMed ID: 16556873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caveolin-1: dual role for proliferation of vascular smooth muscle cells.
    Sedding DG; Braun-Dullaeus RC
    Trends Cardiovasc Med; 2006 Feb; 16(2):50-5. PubMed ID: 16473762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR.
    Harris G; Ghazallah RA; Nascene D; Wuertz B; Ondrey FG
    Otolaryngol Head Neck Surg; 2005 Nov; 133(5):695-701. PubMed ID: 16274795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors.
    Johnson R; Webb JG; Newman WH; Wang Z
    Am Surg; 2006 Jan; 72(1):51-4. PubMed ID: 16494183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular remodeling and protease inhibition--bench to bedside.
    Sluijter JP; de Kleijn DP; Pasterkamp G
    Cardiovasc Res; 2006 Feb; 69(3):595-603. PubMed ID: 16387286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
    Han S; Roman J
    Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.